SUBSCRIBE
SUBSCRIBE

Parkinson’s disease

Pictured: Illustration of neurological health concept
Drug Development
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop
Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo. Phase II studies of the oral treatment will continue in Huntington’s and Alzheimer’s diseases.
April 17, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto
Policy
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease
For the second time in as many years, the FDA has hit Supernus Pharmaceuticals with a Complete Response Letter, citing undisclosed quality and master filing issues for the drug-device combination.
April 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Man holding a Chapter 11 bankruptcy filing
Deals
Acorda Joins Growing Group of Biotechs Filing for Bankruptcy, Divests Assets to Merz
Acorda Therapeutics becomes the latest biotechnology company in 2024 to go bankrupt and shutter its business, following years of financial difficulty. Merz Therapeutics will acquire two commercial medicines from Acorda for $185 million.
April 3, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: 3D illustration of stem cells used for cell therapy
Business
Kenai Emerges from Stealth With $82M Series A, Targets Parkinson’s
Formerly known as Ryne Bio, Kenai Therapeutics emerged on Thursday with backing from several groups and has a cell therapy candidate going after Parkinson’s disease.
March 1, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More
PRESS RELEASES
Press Releases
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
May 7, 2025
 · 
8 min read
Press Releases
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
April 30, 2025
 · 
5 min read
Press Releases
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
April 30, 2025
 · 
7 min read
Press Releases
Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease
April 25, 2025
 · 
2 min read
Press Releases
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
April 16, 2025
 · 
10 min read
Press Releases
XellSmart’s Allogeneic iPSC-derived Cell Therapies for Parkinson’s Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials
April 16, 2025
 · 
5 min read
Press Releases
NKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and Parkinson’s Disease at the 7th China International Biotechnology Conference & Exhibition
April 14, 2025
 · 
5 min read
Press Releases
ATED Therapeutics, Ltd.: New Rapid, Simple Blood Test for Parkinson’s Disease Developed
April 14, 2025
 · 
2 min read
Press Releases
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease
April 9, 2025
 · 
4 min read
Press Releases
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
April 7, 2025
 · 
8 min read
Press Releases
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
April 7, 2025
 · 
9 min read
Press Releases
Development of an Innovative Treatment for Parkinson’s disease: Synucure Therapeutics Announces an Investment of $2.8 million
April 7, 2025
 · 
3 min read
Press Releases
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
April 7, 2025
 · 
10 min read
Press Releases
SPARK NS Selects Eight Projects to Receive Aggregate Funding of Up to $16 Million to Advance Academic Discoveries in Parkinson’s Disease from the Lab to the Clinic
April 4, 2025
 · 
5 min read
Press Releases
Capsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson’s Disease Associated with GBA Mutations (PD-GBA)
April 3, 2025
 · 
4 min read
Press Releases
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
April 3, 2025
 · 
7 min read
Press Releases
Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise
April 3, 2025
 · 
3 min read
Press Releases
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
April 2, 2025
 · 
10 min read
Press Releases
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
April 2, 2025
 · 
5 min read
Press Releases
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
April 1, 2025
 · 
7 min read
Load More